A phase 3 study demonstrated that ritlecitinib was effective and well tolerated in patients with alopecia areata and ≥ 25% ...

The company said it is evaluating its strategic options regarding ADX-097 as it shifts efforts over to pushing bempikibart.

Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment ...

Atopy from food allergies to environmental factors can increase hair loss prevalence among children and adults, according to ...

Alopecia refers to hair loss and can affect the scalp, eyebrows, eyelashes, and other areas of the body. There are different types of alopecia including an | Immunology ...

If you struggle with hair loss, you probably have come up with a hundred possible reasons that could be causing it: from ...

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced a corporate restructuring to ...

Comorbid chronic inflammatory diseases influence the prognosis of alopecia areata, according to study findings.

The goal is to find a cure for alopecia areata, an autoimmune disease that causes hair loss in distinct round patches.

Q32 Bio (Nasdaq: QTTB) has announced a corporate restructuring, shifting its focus entirely to the development of its lead ...